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Abstract
This guidance document is intended to assist the applicant in the preparation and the presentation of an
application, as foreseen in Article 7.6 of Regulation (EC) No 1831/2003, for the authorisation of additives
for use in animal nutrition. It speciﬁcally covers the assessment of the efﬁcacy of feed additives.
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Background and Terms of reference
Regulation (EC) No 1831/20031 establishes the rules governing the Community authorisation of
additives for use in animal nutrition. Moreover, Regulation (EC) No 429/20082 provides detailed rules
for the implementation of Regulation (EC) No 1831/2003 as regards the preparation and the
presentation of applications and the assessment and the authorisation of feed additives.
The Panel on Additives and Products or Substances used in Animal Feed (FEEDAP Panel) has
adopted a series of guidance documents which aim at complementing Regulation (EC) No 429/2008 to
support applicants in the preparation and submission of technical dossiers for the authorisation of
additives for use in animal nutrition according to Regulation (EC) No 1831/2003.
The European Food Safety Authority (EFSA) asked its FEEDAP Panel to:
1) identify from the current guidance documents, those that need to be updated, taking into
consideration the most recent scientiﬁc developments and the experience gained in the
assessment of feed additives;
2) update the guidance documents in need of revision accordingly; this activity can be
conducted in different rounds of activities on the basis of the priorities identiﬁed and on the
feasibility of the revision according the resources available;
3) taking into account the sensitivity and the relevance of some of the guidance documents
under revision and the entity of the revision itself (e.g. substantial or not), consider initiatives
like preparatory info-sessions or public consultations of the draft guidance documents. The
relevant comments received in either step will have to be considered and addressed if
appropriate in the ﬁnal version of the guidance documents.
The ﬁrst of the terms of reference was addressed by a statement of the FEEDAP Panel (EFSA
FEEDAP Panel, 2016), in which it was identiﬁed the need to update most of the guidance documents
that it produced and set priorities for this update.
This output addresses the second and third terms of reference with regards to the update of the
guidance documents dealing with the assessment of the efﬁcacy of feed additives. This guidance
document underwent a public consultation (EFSA, 2018).
Scope of the guidance
This guidance document is part of a series of documents intended to assist the applicant in the
preparation and the presentation of its application for the authorisation of a feed additive, as foreseen
in Article 7.6 of Regulation (EC) No 1831/2003. This document does not substitute for the obligation of
an applicant to comply with the requirements of Regulation (EC) No 1831/2003 and its implementing
rules (Commission Regulation No 429/2008). This document is intended to provide guidance to
applicants for the assessment of the efﬁcacy of additives intended to be used in animal feed, in order
to demonstrate compliance with the requirements of Article 5.3 of Regulation (EC) No 1831/2003. This
guidance is divided into seven sections. The ﬁrst section provides the principles of the assessment of
efﬁcacy. The requirements for efﬁcacy demonstration for the different categories of additives are listed
in Section 2. Section 3 provides information on the number of efﬁcacy studies required for those
additives for which in vivo studies are needed. Sections 4 and 5 describe the principles for in vivo and
in vitro studies, while Sections 6 and 7 provide information on how to report the studies performed by
the applicant or those retrieved from the literature.
Applicants should justify the omission from the dossier of any data or any deviations from the
requirements detailed in this guidance.
1. General principles of efﬁcacy assessment
Regulation (EC) No 429/2008 requires that studies should demonstrate the efﬁcacy for each
proposed use and satisfy at least one of the characteristics set out in Article 5(3) of Regulation (EC)
No 1831/2003, according to the categories and functional groups of feed additives as provided by
Article 6 and Annex I of the said Regulation. Moreover, such studies must permit the evaluation of the
1 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in
animal nutrition. OJ L 268, 18.10.2003, p. 29.
2 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC)
No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications
and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
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efﬁcacy of the additive according to common feed manufacturing, animal husbandry and farming
practices in the European Union (EU). Studies performed outside the EU must permit conclusions to be
drawn on the efﬁcacy of the additive when used in the EU. This does not necessarily exclude the
reporting of studies made outside the EU. Any potential impact on the distinctive features of animal
products should also be investigated during animal efﬁcacy trials (e.g. off-ﬂavour, colour changes).
All efﬁcacy studies submitted should be properly reported and documented in order to allow an
adequate assessment to be made. The studies should be based on the additive(s) for which
authorisation is sought. To avoid confusion, in-house identiﬁers should be avoided unless embedded in
third-party documents. In this case, a statement is required to conﬁrm that the identiﬁer(s) refers to
the additive(s) concerned.
However, the Panel considers that there are some additives for which efﬁcacy is recognised (e.g.
many nutritional additives and ﬂavouring compounds). These additives do not require further
demonstration of efﬁcacy. For others, it is not practical to assess the additive under all possible
conditions of use. Many factors may affect the efﬁcacy of an additive, e.g. nutrition, animal breeds,
composition of feed, management, environment, husbandry. For such additives, the Panel is able to
conclude on the efﬁcacy under the conditions of the studies submitted. From these data, the
Panel may be able to conclude on the potential efﬁcacy of the additive under EU farming conditions.
As a general principle, efﬁcacy can be assessed by means of in vitro studies for those additives which
are intended only to affect the characteristics of feed (i.e. some technological and sensory additives),
while for those which are intended to have an effect in the animal efﬁcacy should be assessed by means
of in vivo studies or, in speciﬁc circumstances, by a combination of in vitro and in vivo studies. The
number of studies required to support the efﬁcacy of an additive will depend on the nature of the
intended effect(s) and the conditions of use of the additive (e.g. target species/categories). The studies
should be based on the additive(s) for which authorisation is sought. Efﬁcacy should be investigated by
comparison of the lowest recommended dose with a control group and designed to allow statistical
evaluation.
Reference can be made to published studies to fulﬁl the requirements listed in the guidance
provided that the active substance/agent in literature studies is identical to that under application or, if
not, would still allow conclusions on the additive under application to be made.
Attention should also be paid to known or potential biological or physico-chemical interactions
between the additive, other additives and/or veterinary medicines and/or components of the diet, where
this is relevant to the efﬁcacy of the additive concerned, e.g. compatibility of a microbial additive with
coccidiostats and histomonostats or organic acids. For details on how to perform compatibility studies
between microbial additives and other additives showing antimicrobial activity, see the guidance on the
characterisation of microorganisms used as feed additives or as production organisms.
Studies involving animals should respect the rules on animal welfare laid down by EU legislation,
particularly those listed in Directive 63/2010/EU.
2. Requirements for the different categories of additives
2.1. Technological additives
When the additive is already authorised for use in food and the intended use of the additive in feed
is the same, no further demonstration of efﬁcacy is generally necessary provided that the effect seen
when used in food could reasonably be expected to be seen when used in feed at the recommended
concentration and that food and feed matrices are of comparable nature.
2.1.1. Technological additives which exert their function in feed
For technological additives intended to affect the characteristics of feed, evidence of the efﬁcacy
should be demonstrated using laboratory-based studies by means of appropriate criteria as reﬂected in
recognised acceptable methods, under the intended practical conditions of use in comparison with
appropriate control feed.
The studies (at least three) should be designed to cover a representative range of feeds to which
the additive will be applied including water for drinking if appropriate.
The appropriate endpoints are indicated in Table 1 for the various functional groups.
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For other technological additives, the endpoints used to assess the function/effect of the additive
should be deﬁned and justiﬁed.
2.1.1.1. Silage additives
For additives intended for the preparation of silage from all forages, a minimum of three separate
tests should be made including one example of each of the following categories;
– Easy to ensile forage: > 3% soluble carbohydrates in the fresh material;
– Moderately difﬁcult to ensile forage: 1.5–3.0% soluble carbohydrates in the fresh material;
– Difﬁcult to ensile forage: < 1.5% soluble carbohydrates in the fresh material.
For additives intended for the preparation of silage from speciﬁc subcategories of forage described
in terms of dry matter, the dry matter range should be explicitly stated. Three tests should then be
made with material representative of the claimed range, where possible using examples of different
botanical origin.
Claims restricted to, or including, feedingstuffs other than forages, require tests speciﬁc to the
particular feedingstuffs.
All studies should demonstrate efﬁcacy in comparison to a negative control made with the same
material for ensiling.
As a general guide, all replicate tests should be made with approximately 1 kg or more of
homogeneous fresh material in a closed laboratory silo with the potential to vent gas and drain efﬂuent.
Other test systems (e.g. wrapped bales) may be used provided that they are consistent with the claims
made and meet the general requirements above (including negative controls). The harvesting and
preparation of the test material must be similar to normal practice. Compaction in the silos should be
constant across replicates. The duration of the study normally should be 90 days or longer at a constant
temperature (recommended range 15–25 °C). Use of a shorter duration must be justiﬁed.
Claims made for silage additives differ and may relate to the preservation process in general, to
speciﬁc aspects of the preservation process or to the aerobic stability of silage once the clamp/silo has
been opened. The observations needed to demonstrate a signiﬁcant beneﬁt for the lowest dose
Table 1: Demonstration of efﬁcacy for technological additives exerting their effect in feed
Functional group Demonstration of efﬁcacy
Preservatives Inhibition of the growth of spoilage microorganisms. Duration of the study should cover the
period for which an effect is claimed. Test materials could be naturally or artiﬁcially
contaminated.
Antioxidants Protection against oxidative damage of key nutrients/components during feed processing
and/or storage. The period for which a protective effect is claimed should be demonstrated.
Emulsiﬁers Formation/maintenance of stable emulsions of otherwise immiscible or poorly miscible feed
ingredients.
Stabilisers Maintenance of the physico-chemical state of feedingstuffs, including the use of coating
agents.
Thickeners Viscosity of the feed materials or feedingstuffs.
Gelling agents Formation of a gel resulting in a change in the texture of the feed.
Binders Pellet durability (hardness, abrasion) or energy consumed during pellet formation.
Anti-caking agents Flowability (angle of repose, frictional forces, compressibility).
Acidity regulators pH and/or buffering capacity in feedingstuffs and/or water.
Silage additives Improved production of silage (better preservation of nutrients).
Inhibition of undesirable microorganisms.
Reduction of efﬂuents.
Improved aerobic stability.
Denaturants Indelible identiﬁcation of feed materials.
Hygiene condition
enhancers
Reduction of contamination with speciﬁc microorganism(s) relevant to feed safety (e.g.
potential human or animal enteropathogens or undesirable bacteria).
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claimed will differ both in nature and sampling time and frequency. As a rule measurements of the
following parameters should be provided in comparison to the negative control3:
• dry matter and calculated dry matter losses (corrected for volatiles);
• pH
• concentration of volatile fatty acids and lactic acid
• concentration of alcohols
• ammonia nitrogen
In addition, other microbiological and chemical parameters should be included as appropriate to
substantiate the speciﬁc claim made (e.g. numbers of clostridia, numbers of Listeria in silage for sheep).
A claim for efﬂuent reduction will be judged against the total volume of efﬂuent produced over the
entire experimental period taking into account the likely effect on the environment (e.g. ecotoxicity of
the efﬂuent, biological oxygen demand). Reduction of efﬂuent production should be demonstrated
directly. The duration of the study should normally be 50 days.
Aerobic stability studies should be of at least 7 days duration after exposure to air and the additive
should provide evidence of stability for at least 2 days longer than that shown by the untreated control.
It is recommended that the experiment is made at an ambient temperature of 20°C and a rise in
temperature of 3°C or more above background taken as indicative of instability. Temperature measures
may be replaced by the measurement of CO2 production. The measurement of dry matter loss and direct
counts of aerobic spoilage organisms may be used as supportive evidence of improved stability.
2.1.2. Technological additives which exert their function in the animal
‘Substances for control of radionuclide contamination’ and ‘substances for the reduction of
contamination of feed by mycotoxins’ are not expected to exert their intended effect until after their
ingestion by the animal. Therefore, the demonstration of efﬁcacy should be based on in vivo studies.
The appropriate endpoints are indicated in Table 2 for the two functional groups.
For other technological additives exerting their effect in the animal, the endpoints used for
assessing the functionality of the additive should be deﬁned and justiﬁed.
2.1.2.1. Substances for reduction of the contamination of feed by mycotoxins
The mycotoxin(s) against which the additive will exert its function and the target species should be
speciﬁed.
A battery of in vitro studies should be submitted to provide evidence of the intended effect of the
additive. However, in vitro studies do not sufﬁciently mimic the conditions in the digestive tract and the
differences between target animals and their metabolism, to fully demonstrate efﬁcacy under practical
conditions and therefore should be supported by in vivo studies. A minimum of three independent4
in vivo studies (generally short term) performed in at least two different locations showing signiﬁcant
effects should be provided to demonstrate efﬁcacy at the lowest recommended dose.
For additives intended to be used in all terrestrial species, efﬁcacy should be demonstrated in vivo
in three major species (at least one study in each) representing different digestive systems (a poultry
species, a non-ruminant mammal and a ruminant). In each case, the studies should include the animal
category for which the lowest maximum content of the respective mycotoxin in feed is set in Directive
2002/32/EC or recommended in Commission Recommendation 2006/576/EC.
Table 2: Demonstration of efﬁcacy for technological additives exerting their effect in the animal
Functional group Demonstration of efﬁcacy
Substances for the reduction of
contamination of feed by mycotoxins
Reduction of the absorption of mycotoxins.
Increased excretion of mycotoxins.
Degradation/transformation of mycotoxins.
Reduced concentration of mycotoxins in food of animal origin.
Substances for control of radionuclides Evidence of reduced contamination of food of animal origin.
3 pH reduction and lactic acid production are central to the ensiling process. However, changes in these parameters alone are
not sufﬁcient to support a conclusion on efﬁcacy in the absence on an effect on silage quality (e.g. evidence of nutrient
preservation or reduction in the rate of aerobic spoilage).
4 Studies are considered to be independent when they are performed with different animals and feeds.
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For additives intended to be used in ﬁsh, speciﬁc studies in ﬁsh (preferably salmonids) are required.
The target mycotoxin content in feed used in studies should not exceed the values given in Directive
2002/32/EC for aﬂatoxin B1 and in Commission Recommendation 2006/576/EC for deoxynivalenol,
zearalenone, ochratoxin A and fumonisins B1+B2 for complete feedingstuffs for the respective animal
species/category and in Commission recommendation 2013/165/EU for T-2 and HT-2. For mycotoxins
without a maximum content established at EU level, the dietary levels chosen should not exert adverse
effects in the target animals.
As a source of mycotoxins, naturally contaminated feed materials are preferred. Alternatively, feed
spiked with mycotoxins could be used if properly justiﬁed. An quantitative analysis of mycotoxins5
present in feed should be provided for each trial.
The experimental design of studies should include at least two groups: one group fed the basal
contaminated diet as such (control) and the other fed the same basal contaminated diet supplemented
with the additive for which authorisation is sought. For mycotoxins without a maximum content
set/recommended, and in order to ensure the absence of adverse effects at the concentrations of
mycotoxins used, an additional control group should be included. In this group, the feed should be free of
these mycotoxins6 and have, in general, the same composition as the feed given to the other two groups.
In general, mycotoxin/metabolites excretion in faeces/urine, concentration in blood/plasma/serum,
tissues or products (milk or eggs) or other relevant biomarkers should be taken as endpoints for the
demonstration of efﬁcacy. The endpoints should be selected according to the mycotoxin and target
species and taking into account the availability of sensitive analytical methods validated for the speciﬁc
matrices. Recommendations on the endpoints are given in Table 3.
Zootechnical parameters should be reported but cannot be used for the demonstration of efﬁcacy.
2.1.2.2. Substances for control of radionuclide contamination
For substances for control of radionuclide contamination, a similar approach to the one for
substances for reduction of the contamination of feed with mycotoxins should be followed. However, a
single study demonstrating positive effects would generally sufﬁce to support the efﬁcacy.
2.2. Sensory additives
When the additive is already authorised for use in food and the intended use of the additive in feed
is the same, no further demonstration of efﬁcacy is generally necessary provided that the effect seen
when used in food could reasonably be expected to be seen when used in feed at the recommended
concentration and that food and feed matrices are of comparable nature.
2.2.1. For substances which, when fed to animals, add colour to food of animal
origin
A minimum of three independent in vivo studies showing signiﬁcant effects should be provided to
demonstrate efﬁcacy for the relevant target species/categories. Evidence of efﬁcacy can be provided
by (i) reference to published studies, where the relationship between a particular substance and the
colour of animal tissues/products is well documented or (ii) in vivo long- or short-term studies.
Evidence should generally be provided for each target species/category for which the application is
Table 3: Most relevant endpoints/biomarkers for substances reducing the contamination of feed by
mycotoxins
Target mycotoxin(s) Most relevant endpoints
Aﬂatoxin B1 Aﬂatoxin M1 in milk/egg yolk
Deoxynivalenol DON/metabolites in blood serum
Zearalenone Zearalenone + a- and b-zearalenol in plasma
Excretion of zearalenone/metabolites
Ochratoxin A Ochratoxin in kidney (or blood serum)
Fumonisins B1 + B2 Sphinganine/sphingosine ratio in blood, plasma or tissues
5 Including at least aﬂatoxin B1 and B2, deoxynivalenol, nivalenol, zearalenone, ochratoxin A, fumonisins B1+B2, T-2 and HT-2,
and any other for which a claim is made should be determined.
6 Below or at least close to the limit of detection.
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made. The change in colour of tissues/products obtained from animals receiving the additive should be
measured using appropriate methodologies (e.g. colour fan, reﬂectance spectroscopy, image analysis).
2.2.2. For substances that add or restore colour in feedingstuffs
Evidence of the efﬁcacy of the additive should be demonstrated using laboratory-based studies by
means of appropriate criteria as reﬂected in recognised acceptable methods, under the intended practical
conditions of use in comparison with an appropriate control feed. The change in colour of feed materials
and/or compound feeds should be measured using appropriate methodologies (e.g. reﬂectance
spectroscopy, image analysis). The studies (at least three) should be designed to cover a representative
range of feeds to which the additive will be applied. The additive should not adversely affect feed quality.
2.2.3. For substances which favourably affect the colour of ornamental ﬁsh and
birds
Evidence of efﬁcacy can be provided by (i) reference to published studies, where the relationship
between a particular substance and the colour of the animals has been established or (ii) extrapolation of
the colouring effect established in poultry or salmonids, as appropriate or (iii) in vivo studies in the target
species. For (i) or (iii), a minimum of three independent long-term in vivo studies showing signiﬁcant
effects should be provided. The change in colour of animals receiving the additive should be demonstrated.
2.2.4. Flavouring compounds
Evidence of efﬁcacy can be provided by (i) reference to literature or (ii) laboratory-based studies
(e.g. sensory panel, electronic nose) or (iii) if the application includes an effect on palatability, by
short-term in vivo studies. For (iii), a minimum of three independent studies showing signiﬁcant effects
should be provided for each target species/category for which the application is made.
2.3. Nutritional additives
No evidence of efﬁcacy is necessary for amino acids naturally occurring in proteins of plants and
animals and their salts, urea and vitamins, provitamins and compounds of trace elements.7
Evidence of efﬁcacy should be provided for amino acid analogues, new forms of compounds of trace
elements, chemically well-deﬁned substances having similar effect to vitamin and urea derivatives.
Evidence can be provided by reference to literature or by in vivo studies. Where evidence from literature
is insufﬁcient to reach a conclusion, a bioequivalence study is considered adequate to demonstrate
efﬁcacy for amino acid analogues, new forms of compounds of trace elements and urea derivatives. For
chemically well-deﬁned substances having similar effect to vitamin, duration and the endpoints of the
in vivo study should be determined depending on the nature of the substance and the effect intended.
For other (novel) nutritional additives at least one long-term efﬁcacy study should be provided.
Generally, it will be sufﬁcient to demonstrate efﬁcacy in one study in a single animal species or category
including laboratory animals. For additives speciﬁcally designed to be effective in a particular animal
species/category (e.g. protected amino acids for ruminants), the same target species should be selected.
2.4. Zootechnical additives
A minimum of three independent in vivo studies showing signiﬁcant effects should be provided to
demonstrate efﬁcacy for the relevant target species/categories. These should be carried out at least at
two different locations, at least one of which should be in the EU. Efﬁcacy studies should always
include the lowest incorporation level (mg/kg complete feed)/lowest daily level (mg/head per day)
proposed by the applicant.
2.4.1. Additives affecting animal production or performance
For those additives affecting animal production or performance of animals, long-term efﬁcacy
studies should be provided unless the use of the additive/active substance is restricted to speciﬁc
short-term periods (see Section 4.2.2.1). Depending on the properties of the additive, outcome
measures may be based on performance characteristics or reproduction parameters.
7 Applications for vitamins, provitamins and compounds of trace elements should consider the classiﬁcation of these substances
by the scientiﬁc community.
Guidance on the assessment of the efﬁcacy of feed additives
www.efsa.europa.eu/efsajournal 9 EFSA Journal 2018;16(5):5274
For enzymes which affect the digestibility of phytate phosphorus, polysaccharides or protein, short-
term (balance) studies can substitute for long-term studies provided that properly deﬁned and speciﬁc
methods are applied. For phytases, polysaccharidases and proteases improved utilisation of dietary
phosphorus, metabolisable energy and protein, respectively, must be demonstrated in these studies.
Improved utilisation can be demonstrated for:
– phytases by total P retention in balance trials or P digestibility plus partial P (bone) retention.
– polysaccharidases by increased metabolisable energy in balance trials.
– proteases by ileal digestibility of amino acids in poultry otherwise by nitrogen balance study.
Apparent digestibility studies alone are not considered sufﬁcient to demonstrate the efﬁcacy of
these enzymes, with the exception of sows for technical and ethical reasons.
2.4.2. Additives favourably affecting the environmental consequences of animal
production
For additives which favourably affect the environment by direct or indirect means (e.g. reduction of
nitrogen or phosphorus excretion, methane production or odour), efﬁcacy for the target species can be
demonstrated by short-term studies. These studies should take into consideration the possibility of an
adaptive response to the additive.
2.4.3. Additives affecting the characteristics of food of animal origin
For those additives affecting the characteristics of food (other than sensory additives which affect
the colour of food), the choice of long-term or short-term studies to demonstrate the efﬁcacy for these
additives will depend on the nature of the substance and their intended purpose. The selection of the
endpoints should be properly justiﬁed.
2.4.4. Additives affecting animal welfare
For additives favourably affecting welfare, the choice of long-term or short-term studies to
demonstrate the efﬁcacy will depend on the nature of the substance and their intended purpose. The
selection of the endpoints should be properly justiﬁed. For example, long-term studies would be
needed to detect changes in morbidity/mortality while short-term studies may be sufﬁcient to measure
reduced stress levels as monitored by metabolic indicators.
2.4.5. Other additives
The intended effect of the additive should be clearly speciﬁed. The choice of long-term or short-term
studies to demonstrate the efﬁcacy for other additives under this category will depend on the nature of
the substance and their intended purpose. The selection of the endpoints should be properly justiﬁed.
2.5. Coccidiostats and histomonostats
These additives protect animals from the consequences of an invasion of Eimeria spp. or
Histomonas meleagridis. The text below provides guidance for the assessment of efﬁcacy of
coccidiostats in poultry and rabbits. For applications covering other animal species or histomonostats,
the requirements below should be adapted and justiﬁed.
The capacity of anticoccidial substances to control coccidiosis should be demonstrated by targeting
speciﬁc endpoints (e.g. lesion/faecal score, oocyst excretion, morbidity, coccidiosis-related mortality).
Data on body weight and feed intake should be provided as supportive information.
Efﬁcacy data should derive from two types of target animal experiments:
• artiﬁcial infection to simulate use conditions (e.g. ﬂoor pen studies with poultry, battery cage
studies with rabbits)
• anticoccidial sensitivity tests (AST) for poultry, ﬁeld studies for rabbits
The geographical location of the studies is considered of less importance compared to the virulence
of the inoculum.
The minimum proposed inclusion level should be tested in all ﬂoor pen studies with poultry/battery
cage studies with rabbits and AST/ﬁeld studies.
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Due to the inherent weaknesses of ﬁeld trials in poultry (usually no negative control, short duration
of use of the coccidiostat under examination in shuttle programmes, inadequate characterisation of
endpoints), these trials may be considered as supporting evidence only.
2.5.1. Floor pen studies with poultry/battery cage studies with rabbits
For ﬂoor pen studies with poultry/battery cage studies with rabbits, three studies with different
inocula from different geographical locations within the EU are required. The studies should be
conducted not more than 5 years before the date of submission of the application. A negative control
(without a coccidiostat) is essential. The design of such a study usually consists of three groups:
• uninfected untreated control (UUC)
• infected untreated control (IUC)
• infected treated (IT)
A fourth optional group may be included:
• uninfected treated (UT)
The study duration is usually equal to that required for long-term efﬁcacy studies (see
Section 4.2.2.1). The measurement of the different endpoints should be done at least 6–7 and 14 days
after inoculation and at the end of the study. It is recommended to expose all animals in the IUC and
IT groups to the inoculum and not to rely on seeder animals.
2.5.2. Anticoccidial sensitivity tests for poultry
Three anticoccidial sensitivity studies done with inocula from different geographical locations within
the EU and showing signiﬁcant and positive results are required for poultry. The studies should be
conducted within 2 years before the submission of the application.
Sensitivity tests should be performed according to the principles established by Chapman (1998)
and following the guidelines published by Holdsworth et al. (2004).
Animals should be fed the same basal diet until grouping at which time the experimental diets should be
introduced. Allocation of replicates to treatment groups should be done 1 or 2 days before inoculation at
day 13–16 of age. Examination of endpoints should normally be done at least 6–7 days after inoculation.
Zootechnical parameters should be reported for this experimental period (from grouping until completion).
2.5.3. Field trials in rabbits
Three studies made in different geographical locations within the EU should be provided. The group
receiving the coccidiostat under application should be compared to either an untreated group (negative
control) or to a group given another authorised coccidiostat (positive control). If a negative control is
used, the treated group should show signiﬁcant differences in the relevant endpoints. Otherwise, the
studies should indicate that the coccidiostat is at least as effective as the coccidiostat used for comparison
purposes. Field studies based on shuttle or rotation programmes will not be considered.
2.5.4. Inocula
The inoculum is the critical factor in the models used in studies with artiﬁcial infection. The
inoculum (sporulated oocysts) should represent EU ﬁeld strains of coccidia that have been exposed to
currently approved coccidiostats but should not originate from operations where birds have been
vaccinated against coccidia in the previous two ﬂocks. Laboratory strains are not acceptable. For
inocula used in the AST, the Eimeria ﬁeld strains should ideally undergo one, but in any case not more
than three, passage(s) provided virulence is retained.
Mixed inocula should be selected from the following Eimeria species based on current prevalence: in
chickens: E. brunetti, E. acervulina, E. maxima, E. mitis, E. tenella and E. necatrix; in turkeys:
E. meleagrimitis and E. adenoeides; in rabbits: E. magna, E. media, E. perforans, E. ﬂavescens,
E. intestinalis and E. stiedae. For minor poultry species, the most typical Eimeria species encountered
should be selected.
Virulence titration studies should be performed with each inoculum used in the different studies. The
study should include birds in an UUC group and multiple groups given increasing numbers of oocysts. The
study follows the principle described for screening tests considering the age of animals at inoculation and
the experimental period and it is done with a small number of animals per group. Virulence is assumed
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when weight gain is depressed in the experimental period by 25% in chickens and 15% in turkeys and/or
intestinal lesion score increased by a minimum of two units on a ﬁve-point scale8 in chickens or a
comparable increase in faecal score for turkeys. In addition, mortality/morbidity should be reported.
For rabbits, no numerical limits for establishing sufﬁcient virulence of an inoculum can be given.
However, the same criteria as described above can be applied and results showing signiﬁcant
differences used to describe a pathogenic dose.
The protocol used in virulence titration studies and the full study report should be submitted.
3. Number of in vivo efﬁcacy studies required
The number of independent in vivo efﬁcacy studies required depends on the number of target
species/categories for which application is made.
3.1. Single animal category
If the application covers only one animal category, the studies required in Section 2 should be
performed in that animal category.
3.2. Multiple categories of the same species of food-producing animals
In principle, conclusions from studies in fattening animals are extended to include animals of the
same species that are reared for reproduction, e.g. from chickens for fattening to chickens reared for
laying/breeding, from turkeys for fattening to turkeys reared for breeding.
Conclusions from studies in weaned piglets are taken to include suckling piglets for the period in
which solid feed is given.
Efﬁcacy data cannot generally be extrapolated between categories of the same species at different
production stages (e.g. from chickens for fattening to laying hens).
3.3. Multiple species of food-producing animals
When the application covers several target species/categories, it is recognised that it may be
unrealistic to expect studies in all potential target species for which application is made. Therefore,
interspecies extrapolation of data can be applied.
In principle, data can be extrapolated between physiologically similar species (Table 4). The degree
to which species are physiologically related is judged predominantly in terms of gastrointestinal
function. Similarities in metabolism also are considered. However, the interspecies extrapolation can be
applied only in case the animals are kept for the same purpose, i.e. meat production or reproduction
(including milk or egg production), the mode of action can reasonably be presumed to be the same
between species and the effects claimed are the same.
Table 4: Extrapolation of efﬁcacy data from certain species to other physiologically related species
From To physiologically related species
Chickens for fattening other poultry for fattening (e.g. turkeys, ducks, geese, pheasants,
quail, guinea fowl, ostrich) and ornamental birds
Laying hens other birds kept for egg production or breeding(a) (e.g. turkeys ducks,
geese, pheasants, quail, guinea fowl, ostrich)
Piglets(b) or pigs for fattening other growing Suidae
Sows other reproductive Suidae
Calves or cattle for fattening other growing ruminants (e.g. sheep, goat, buffalo) at the
corresponding developmental stage
Dairy cows other dairy ruminants (e.g. goat, sheep, buffalo)
Salmon or trout ornamental ﬁsh
Horses other Equidae
Rabbits other Leporidae
(a): Limited to the effects demonstrated in the laying hens.
(b): Piglets: either weaned piglets or suckling and weaned piglets.
8 Five point scale as described in Johnson J. and Reid W.M. (1970): Anticoccidial drugs: Lesion scoring techniques in battery and
ﬂoor-pen experiments with chickens. Experimental Parasitology 28 (1): 30–36.
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The minimum effective level in the physiologically related species would be the same as established
in the species/category from which data is extrapolated.
When the application covers multiple species/categories, the minimum number of independent
studies showing the intended effect is shown in Table 5.
For applications covering all food-producing animal species, efﬁcacy should be demonstrated in
species with different digestive systems. Therefore, studies should be provided to support efﬁcacy for
all pigs, all poultry, all ruminants and all ﬁn ﬁsh according to the Table 5.
For certain types of additives, the requirements for efﬁcacy studies above may be modiﬁed:
– For substances for reduction of the contamination of feed by mycotoxins, radionuclide binders
and nutritional additives, the number of studies and the target species are given in Section 2.
– For coccidiostats and histomonostats, speciﬁc studies are required for chickens and turkeys. For
those intended to be used in minor species, if efﬁcacy has been demonstrated in a major species,
then one additional study (preferably a ﬂoor pen study) incorporating the most typical Eimeria
species encountered should be provided for each additional species to a maximum of three.
3.4. Pets and other non-food-producing animals
The requirements for the different categories/functional groups of additives apply.
1) For additives for which efﬁcacy has been demonstrated in a food-producing animal species,
one in vivo study is required for each target pet/non-food-producing species to a maximum
of three studies in total provided that the intended effect is the same.
2) Where the intended effect in the pet/non-food-producing species is not the same as that
described for the food-producing animal species or when efﬁcacy has not been demonstrated
in food-producing animal species, three in vivo studies in one pet/non-food-producing
species are required. If the application is made for more than one pet/non-food-producing
species, a single additional study would be required for each additional target species to a
maximum of three species in total.
Table 5: Minimum number of independent studies and target species required for the assessment
of efﬁcacy in applications covering multiple species/categories
Application for Number of studies required and species
All growing poultry species
(chickens for fattening, turkeys for fattening and minor
growing poultry species)
3 in chickens for fattening
All poultry species
(chickens/hens, turkeys and minor growing and
reproductive)
3 in chickens for fattening
3 in laying hens
All growing pigs
(piglets, pigs for fattening and minor growing porcine)
3 in weaned piglets
3 in pigs for fattening
All pigs
(piglets, pigs for fattening, sows and minor growing and
reproductive porcine species)
3 in weaned piglets
3 in sows
All growing ruminants
(calves, cattle for fattening, sheep and goats for
fattening, other minor growing ruminants)
3 in calves
3 in cattle for fattening
All ruminants
(calves, cattle for fattening, cows, sheep and goats for




All ﬁn ﬁsh 3 in salmonids (salmon or trout)
3 in other species (1 study in each)
Crustaceans 3 in shrimp/crustaceans
Rabbits
(growing and reproductive)
3 covering both growing and reproductive animals
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4. In vivo efﬁcacy studies
In vivo animal studies are foreseen for all additives which exert the intended effect in the target
species. Generally, zootechnical parameters (e.g. growth, feed conversion, milk yield, laying
performance, carcass composition, reproduction performance) can only be reliably measured in long-
term efﬁcacy studies, whereas effects on other parameters (e.g. absorption, digestibility, excretion,
retention) may be better demonstrated in short-term studies. The choice of short- or long-term studies
or a combination of both will depend on the effect and/or mode of action of the additive.
Such experiments should use numbers and species/categories of animals appropriate to the
conditions of use proposed. Studies should be designed to demonstrate the efﬁcacy of the lowest
recommended level of the additive by targeting sensitive parameters usually in comparison to a
negative and, optionally, a positive control group. No single design is recommended, ﬂexibility being
provided to allow for scientiﬁc discretion in the design and conduct of the studies.
The experimental design used must be justiﬁed according to the additive function, use, animal species
and category. The trials should be conducted such that their health and husbandry conditions do not
adversely affect the interpretation of the results. The positive and negative effects should be described
for each experiment. Trials should follow the criteria established by recognised, externally audited, quality
assurance schemes (e.g. good laboratory practice, good clinical practice). Evidence should be provided
that the work was done by qualiﬁed personnel using appropriate facilities and equipment and responsible
to a named study director. Studies conducted outside the EU must follow the same quality standards.
4.1. General requirements for the in vivo studies
4.1.1. Test item
Efﬁcacy studies should be based on the additive(s) for which application is made. Any deviations
because of practical or other considerations should be justiﬁed. A certiﬁcate of analysis of the test item
used in the study should be provided.
4.1.2. Route of delivery
Use of the additive in efﬁcacy studies should respect the proposed conditions of use (e.g. with
regard to use level, route, number of administrations, duration of administration).
For additives intended for use in feed and water, the oral administration routes are principally
considered as bioequivalent. Therefore, studies can be made in either feed or water, or a mixture of both,
provided that the exposure of the animal is the same. Otherwise, studies for each route would be required.
For an additive for which data are already available allowing a minimum effective level to be
established in feed, the corresponding concentration in water can be derived from feed intake. The
same principle would apply when the effective level has been established in water. For poultry, pigs
and rabbits, the water intake would be 2–3 times the amount of dry matter feed intake. In ruminants
and horses, concentrations of an additive cannot be consistently extrapolated from feed to water using
a ﬁxed ratio of feed to water intake. However, these concentrations can be converted to daily amounts
which can then be equally administered via feed or water. Consequently, the conversion of feed
concentration to water concentration should be done on the basis of the daily ration.
The concentration of the active substance(s)/agent(s) in the feedingstuffs/water should be
conﬁrmed by analysis.
4.1.3. Experimental groups
The design of an efﬁcacy study includes a minimum of two groups:
– a control group
The feed and water of the control group should normally not contain the additive tested.
Where studies are required to demonstrate that the additive contributes to the animals’
nutritional requirements, the feed of the control group should contain the nutrient at
concentrations marginally below the animals’ requirements.
– a use-level group
The feed/water of the use level group should normally be supplemented with the additive at
the lowest proposed use level.
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For some additives (e.g. nutritional, some colouring agents), the appropriate level of
incorporation may be deﬁned by the diet to which it is applied.
Additional groups with the additive supplemented at different levels or a positive control may be
included, as appropriate.
4.1.4. Animals
Animals used should be healthy and preferably from a homogeneous group. Housing and
husbandry conditions should be adequate for the purpose of the study and conform to animal welfare
regulations. Routine vaccinations across all groups are acceptable, but preventive treatments with
antibiotics/antimicrobials before the start of the trial should be avoided.
Any treatments with veterinary medicinal products during the course of the study should not
interact with the proposed mode of action of the additive. The acceptability of trials in which animals
are treated with veterinary medicinal products during the course of the study will depend on a variety
of factors, including the number of animals treated, duration of the treatment, distribution between
experimental groups and severity of the disease. The acceptability of these studies will be assessed on
a case-by-case basis. Studies with an abnormally high mortality rate (i.e. above current European
commercial production standards), will not be accepted.
The recommended age/weight for the different species/categories at the start of the study is
detailed in Section 4.2.2.1.
4.1.5. General endpoints
For all in vivo studies, the following parameters should be reported: clinical observations including
general health status, morbidity/mortality, feed intake and water intake for those additives
administered via water, initial and ﬁnal body weight, milk/egg production (as appropriate).
Speciﬁc endpoints will depend on the nature of the additive and its intended effects. More
information can be found in Section 2 and Section 4.2.2.2 below.
4.1.6. Statistical considerations
4.1.6.1. Design of the experiment
The experimental unit is the smallest entity to which a given treatment is applied. If animals are
penned in groups and all the animals in the pen share the same feed source (and feed intake is not
measured individually), then the experimental unit for all parameters is the pen, not the individual
animal.
Experimental units allocated to the various experimental groups should not differ in a systematic
way. Therefore, a recognised method of randomisation should be used to allocate treatments to the
experimental unit (e.g. pen, animal). The setting conditions (e.g. temperature, light exposure) should
be the same for the various groups including housing, husbandry and diet/water administration. A
randomised block design should be preferably used to control for experimental settings like location
within facilities. The same design is also recommended in case of large experiments to ensure
concurrency in measurements/determination of endpoints across treatments. Other designs might be
also appropriate, in which case the applicant should justify the rationale for the design chosen.
In case of a signiﬁcant variability across animals of factors which could inﬂuence the outcome of
the study, animals should be stratiﬁed before being randomly allocated to pens/cages/treatments.
These factors might include initial body weight, gender, age, stage of lactation, milk yield, parity, egg
production.
A proper method for randomisation should be used in order to allow allocation concealment (no a
priori knowledge of group assignment). In practice, the randomisation process must ensure that
investigator cannot inﬂuence the allocation of units to the various groups. It is recommended to
implement blinding of the caregivers and investigators, where possible, for instance using a proper
codiﬁcation of the treatment to be administered. Blinding is mandatory in cases where the endpoints
are gained by expert judgement (e.g. colour by colour fan, lesion score, pathology).
4.1.6.2. Sample size
Statistical considerations should be used to determine the size of the sample used to evaluate the
intended effect(s). The setting of the null and alternative hypotheses should be done in light of the
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problem formulation. Difference testing should be used to conﬁrm statistical superiority or inferiority
(i.e. alternative hypothesis stating a difference exists) and tests for non-inferiority should be done for
experiments aiming at demonstrating non-inferiority between treated groups and a positive control
(e.g. bioequivalence study). Additional considerations need to include: (i) the magnitude of the effect
that the study is designed to detect at the substance lowest recommended level; (ii) the expected
variability of the effect; (iii) the expected direction of the effect; (iv) an adequate statistical power; and
(v) the conﬁdence level. When the direction of the effect is predictable, a one-sided test should be
used. A two-sided test is recommended in all other cases. The applicant should justify the selection of
the endpoints chosen to determine the sample size.
As a guide, a power greater than or equal to 80% (75% for ruminants, minor species, pets and
non-food-producing animals) should be ensured. Generally, when testing difference, a conﬁdence level
of 90% is adopted for ruminants, minor species, pets and non-food-producing animals and 95% for all
other animal species and categories.
4.1.6.3. Statistical analysis
The statistical analysis should be performed at the level of experimental unit using models that
allow comparing treated and control groups whilst controlling for factors that could inﬂuence the
outcome of the experiment whenever possible. The class of generalised linear mixed models
(McCullagh and Nelder, 1989), known as GLMM, offers a suite of methods ﬂexible enough to ﬁt most
of the experimental settings. Typically, this type of models includes the treatment and other
stratiﬁcation variables (e.g. age) as ﬁxed factor and blocking factors, if any, as random (e.g. animal/
pen location). The response variable is the endpoint under investigation. Under certain conditions, a
log or other transformations can be needed in order to linearise the relationship with the explanatory
factors. Depending on the type of response variable (i.e. continuous, quantal, dichotomic), different
kinds of statistical tests and distributional assumptions could be required. The applicant is requested to
assess which one is more appropriate and to provide the rationale of the choice. An indicator of quality
of ﬁt should always be provided.
The analysis of variance is one of the models included in the GLMM class. When using this method,
Scheffe, Dunnet, Tukey, Bonferroni tests or other comparable tests should be used any time multiple
comparisons are performed concurrently. Independently from the outcome of tests of normality, non-
parametric tests should be used when only a low sample size is available and/or there is evidence of
outliers and/or skewness and/or multiple modes. However, applicants are encouraged to use a
sufﬁcient number of experimental units to allow for parametric tests to be performed in order to
achieve a higher power. When different substances are assessed concurrently using the same control,
the statistical evaluation should be done considering only the control and the groups treated with the
additive under assessment.
Pooling of data from different studies of comparable design may be done and may substitute for a
single efﬁcacy study, provided that the interaction treatment x study is not signiﬁcant.
4.2. Typology of in vivo studies
4.2.1. Short-term efﬁcacy studies
Short-term studies are deﬁned as studies with duration shorter than the minimum duration given in
Section 4.2.2.1. They ﬁnd particular application in the measurement of bioavailability/bioequivalence of
an additive, intestinal absorption and/or excretion of nutrients or other substances, for the assessment
of feed palatability and colouring potency in food of animal origin. Other short-term efﬁcacy studies
with animals may be proposed as appropriate.
4.2.1.1. Bioavailability/bioequivalence studies
Bioavailability is deﬁned as absorption/transport of the active substance(s)/metabolite(s) to the
target cells/tissue(s) where it exerts a typical function/effect. Bioavailability will be evaluated by the
corresponding speciﬁc endpoints (observable or measurable biological, chemical or functional events),
depending on the nature of the additive.
Bioequivalence is used to assess the expected in vivo biological equivalence of two additives. If two
products are said to be bioequivalent, it means that they would be expected to be, for all relevant
effects, the same (needs statistical conﬁrmation by a non-inferiority test). Such studies may be used to
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demonstrate the level at which a novel form or source of a nutritional additive or an additive which
colour food of animal origin can substitute for an equivalent additive already authorised or established.
4.2.1.2. Digestion/balance studies
The outcome of a digestion study is digestibility (e.g. apparent or true, faecal or ileal) of a nutrient
as inﬂuenced by the additive. Balance studies are preferred because they deliver additional information
on quantitative excretion and retention of a nutrient/energy. Digestibility studies in which animals are
cannulated are discouraged due to animal welfare considerations.
Digestibility/balance studies should be performed considering an adequate period of adaptation to
the diet (and experimental conditions). The minimum duration of this preperiod depends on the species:
3 days for poultry, pigs, dogs and cats, 14 days for ruminants and 7 days for equidae. For studies using
the total collection method of faeces/urine/excreta, the duration of the collection should be 3–4 days in
poultry, dogs and cats, 4–6 days in pigs and horses, 5–7 days in ruminants. Measures should be taken
(e.g. slight restricted feeding) to ensure that the same quantity of feed is consumed sufﬁciently before
the start of collection (e.g. at least 1 day for poultry, 2 days for pigs, ruminants and equidae) and during
the collection period. The use of a marker in the diet would avoid the need for quantitative collection of
faeces, the same time given above for the preperiod and collection period should be retained.
In studies in layers, cows and sows, special considerations should also be given to the output (e.g.
eggs, milk, litter). For applications in gestating and lactating sows, digestibility studies should be
performed in both gestating and lactating sows.
Digestibility studies in ﬁsh are discouraged; retention studies should be made instead. Retention
studies in ﬁsh aim at measuring body composition.
4.2.1.3. Palatability studies
Palatability studies should provide a free choice of feed (simultaneous access to control and test
feed) to the animal. The experimental design should exclude the possibility that the results are
inﬂuenced by the position in which the individual feed types are offered. The minimum duration of
studies of this type is two periods of 5 days each, with an intermediate period in which only the
control feed should be provided.
The two diets should be essentially equal in composition, with the only difference being the
presence of the additive in the test diet at the proposed inclusion rate (analytically conﬁrmed).
Feed intake should be recorded at least once daily and reported accordingly.
A similar design should be applied for additives intended to be used in water. In that case, feed
intake should also be monitored.
4.2.2. Long term efﬁcacy studies
4.2.2.1. Duration of the long-term efﬁcacy studies
Generally, the duration of efﬁcacy trials should correspond to the application period claimed. The
necessary minimum duration of efﬁcacy trials depends on the animal species/category and is reported
in Table 6.
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For minor species not included in the table above, the duration of the studies should correspond to that
of the physiologically related major species listed in Table 4 unless properly justiﬁed. For all other species/
categories, the minimum duration should be 42 days for growing animals and 56 days for adult animals.
If an additive is applied for a speciﬁc and shorter period than that given in the table above, it
should be administered according to the proposed conditions of use. However, the observation period
should not be shorter than 28 days and should involve the relevant endpoints (e.g. for sows for
reproduction, the number of piglets born alive when considering the gestation period, or the number
and weight of weaned piglets when considering the lactation period).
Table 6: Minimum duration of long-term efﬁcacy studies
Category
Deﬁnition of the animal
category
Start Minimum duration
Piglets (weaned) Young animals having completed
the suckling period
≤ 7 days after
weaning
42 days
35 days if growth rate is
≥ 0.5 kg/day
Pigs for fattening Animals intended for meat
production until day of transport to
slaughterhouse
≤ 35 kg Until slaughter, but not less
than 70 days




For effects on reproduction: two
cycles (from insemination/
mating until weaning).
For effects on piglets, preferably




Birds raised for fattening 1 day of age 35 days





Turkeys for fattening Birds raised for fattening 1 day of age 84 days
Calves Calves which are reared for
reproduction, veal production or
beef production
1–4 weeks of age 56 days




≤ 6 months of age
84 days
Cows Lactating cows 4–8 weeks after
calving
84 days
Lambs/kids Young animals reared for
reproduction or meat production
1–4 weeks of age 56 days
Sheep/goats Lactating animals 4 weeks after
parturition
84 days
Salmon and trout Growing salmonids Trout ≥ 10 g
Salmon ≥ 50 g
84 days
Rabbits Rabbits that are reared for
reproduction or meat production
1 week after birth 42 days




For effects on reproduction:
Two cycles
For effects on kits: preferably
from 2 weeks before parturition
until end of weaning period.




Guidance on the assessment of the efﬁcacy of feed additives
www.efsa.europa.eu/efsajournal 18 EFSA Journal 2018;16(5):5274
4.2.2.2. Endpoints
The endpoints to be measured depend on the effects which are expected from the additive (see
Section 2). A non-exhaustive list of endpoints for some common effects is given below.
Performance parameters and related parameters
For all studies, feed intake, initial and ﬁnal body weight, body weight gain, feed to gain ratio, water
intake for those additives administered via water, should be provided. Additionally, clinical observations
including general health status, morbidity and mortality should be monitored.
Additional parameters for:
– laying hens: laying rate, egg weight, feed to egg mass ratio, egg mass/hen per day.
– breeding hens: laying rate, fertility, hatchability and chick viability.
– dairy animals: milk production (also fat-corrected milk), milk composition (total solids, protein,
fat, lactose and urea), protein, fat and lactose yield and somatic cell counts.
– sows: number of piglets born, piglets born alive, litter weight at birth and at weaning, number
of piglets weaned, weaning to oestrus interval.
– ﬁsh: speciﬁc growth rate.
Product quality/composition
When measuring changes in the product quality or composition as an intended effect of the use of
the additive, the following endpoints can be considered as appropriate.
– Composition: e.g. nutrient content.
– Physical/technological properties: e.g. water-binding capacity, oxidative stability.
– Sensory modiﬁcation of food products: e.g. colour, taste, smell, texture.
The sensory properties of the food products should be measured, preferably by objective methods.
However, it is recognised that some parameters can be better assessed by means of, e.g. a trained
panel or other subjective methods.
– Hygiene quality of food products: e.g. numbers of spoilage organisms, potential human or
animal enteropathogens.
Studies should clearly identify the target microorganisms. These should be enumerated and
their prevalence either in faeces/intestinal contents or in the carcass established. Ideally, the
measurements of the pathogens should be done in the food products.
Other endpoints may be proposed and justiﬁed.
Environmental effects
Direct effects on the environment may include, for example, reduction on methane, ammonia,
carbon dioxide emissions and reduction of odour or odorous compounds.
Indirect effects on the environment may result from an increased nutrient utilisation and result in a
reduced excretion of, e.g. nitrogen, phosphorus and sulphur, if appropriate dietary adjustments are made.
Faecal consistency
It is recommended to use objective measurements such as dry matter content of faeces. Subjective
observations of faecal consistency alone are discouraged. If used, continuous subjective observations
should be complemented with periodic objective measurements.
Welfare
Suitable and reproducible endpoints should be proposed and justiﬁed.
4.3. Studies on the quality of products when this is not the effect
claimed
Evidence should be provided that the additive does not have a negative effect or another unintended
effect on sensory and nutritional (and hygienic and technological if appropriate) characteristics of food
deriving from animals fed with the highest proposed level of the additive. Evidence can be based on
physiological/metabolic considerations or given by reference to published literature. Otherwise, speciﬁc
studies should be provided. Appropriate endpoints may be found under Section 4.2.2.2.
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Omission of these studies should be adequately justiﬁed.
5. In vitro studies
For additives affecting the characteristics of feed, efﬁcacy should be demonstrated using laboratory-
based studies. Efﬁcacy studies should be based on the additive(s) for which application is made. A
certiﬁcate of analysis of the test item used in the study should be provided. The concentration of the
active substance(s) or agent(s) in the feedingstuffs/water should be conﬁrmed by analysis. The
experimental design and methodology used should be appropriate to the intended effects of the additive.
Studies should be designed to demonstrate the efﬁcacy of the recommended level(s) of the additive by
targeting sensitive parameters in comparison to a control group. The study should be designed to cover a
representative range of materials to which the additive will be applied (feed materials, complete or
complementary feed or water depending on the intended use).
The experimental design should consider sufﬁcient number of observations to allow an adequate
statistical analysis. Results of each test/subset should be statistically evaluated and a conﬁdence level
of 95% adopted. Independently from the outcome of tests of normality, non-parametric tests should
be used when only a low sample size is available and there is evidence of outliers and/or skewness
and/or multiple modes. However, applicants are encouraged to use sufﬁcient replicates to allow for
parametric tests to be performed in order to achieve a higher power. When different substances are
assessed concurrently using the same control, the statistical evaluation should be done considering
only the control and the groups treated with the additive under assessment.
All trials should follow the criteria established by recognised, externally audited, quality assurance
schemes (e.g. good laboratory practice or ISO standards). Evidence should be provided that the work
was done by qualiﬁed personnel using appropriate facilities and equipment and responsible to a named
study director.
6. Reporting of efﬁcacy studies
For each efﬁcacy study, a study report should be submitted describing the objectives, materials and
methods, results and conclusions. The original study protocol should be included; any deviations from the
original protocol should be clearly indicated and justiﬁed in the ﬁnal report. The reports should include
the raw data in digital format and detailed results including descriptive statistics, statistical tests and
model outcomes. Reports for in vivo studies should start with a trial protocol data sheet (Appendix A)
followed by the full study report. International units should be used to express the results.
It is recommended that the study report follows the structure detailed below and contain the
following information. Applicants are encouraged to follow the recommendations of the EFSA guidance
on statistical reporting (EFSA, 2014).
Title: The title should provide a concise and clear description of the study, including the type of study,
the product under assessment and animal species/category.
Summary: The summary should include the objectives, a description of the design and methods, the
main results and the conclusions of the study.
Objectives: The objectives of the study should be clearly described.
Materials and methods: Methods, apparatus and materials used, details of the species, breed or
strain of the animals, their number and the conditions under which they were housed and fed. In
particular, the following should be recorded and reported:
Ethical statement
1) Indicate compliance with national or institutional guidelines for the care and use of animals.
Animals, housing and husbandry
2) Animals: species (for aquatic species intended for human consumption: identiﬁcation should
be made by their colloquial name followed in parenthesis by the Latin binomial), breed, age
(and size/length for aquatic species), initial body weight, sex, identiﬁcation procedure,
physiological stage and general health.
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3) Husbandry conditions: feeding and rearing conditions (pen/tank size, stocking density,
temperature, lighting); for aquatic species water quality including water ﬂow rate, water
temperature and salinity, where relevant.
4) Diets: description of manufacture and quantitative composition of the diet(s) in terms of
ingredients used, relevant nutrients (calculated and analysed values) and energy (digestible,
metabolisable or net). In addition for studies with enzymes, the diets should be analysed for
the enzyme-speciﬁc substrate.
Study design
5) Study location, dates and responsible individuals.
6) Study duration.
7) The type of design of the study (e.g. factorial, stratiﬁed, crossover).
8) Experimental groups: number of treatment and control groups, numbers of replicates
(experimental unit) per group and number of animals per replicate.
9) The experimental unit (e.g. individual animal, pen) should be indicated.
10) The basis for the different measurements (e.g. individual animal, pen) should be indicated
for each parameter measured.
11) Rationale for the selection of the number of animals/replicates used (sample size
calculation). Power analysis should be provided.
12) Steps taken to minimise bias including randomisation and blinding (see Section 5.1.1 of the
EFSA guidance on statistical reporting).
13) Test item: Intended concentration of the active substance(s) or agent(s) in the
feedingstuffs.
Experimental procedures
14) The procedures carried out to the different experimental groups should be detailed. These
should include the parameters/endpoints measured, indicating when and how they were
measured, and information on the methods of analysis.
15) The health of the animals should be monitored, morbidity and mortality (including culling)
recorded.
16) The methodology to correct feed to gain ratio for mortality (including culling) should be
reported.
Statistical methods
17) The result of the power analysis should be reported.
18) The methods to perform statistical analysis should be stated, including those used to
identify outliers and handle missing data. If any relevant data points are excluded from the
model (e.g. outliers), a justiﬁcation should be given.
19) Describe any methods used to assess whether the data met the assumptions of the
statistical approach.
Results: Results of the study should be presented for all endpoints considered in the study. Tables
should be used to summarise the results from treatments. For all endpoints which are measured on
individual animals in a pen, a summary parameter of the endpoint in the experimental unit should be
used (e.g. mean for continuous measurements such as body weight, median and counts for quantal
measurements such as severity of an outcome or mortality). Summary parameters should always be
adjusted for losses (mortality/culling). The distribution of losses within the treatment groups should be
assessed to avoid the risk of introducing a bias.
20) Health status of the animals, morbidity and mortality including culling. The timing and preva-
lence of any unexpected/undesirable incident/effect in individuals or groups. Therapeutic/
preventive treatments if any must be recorded. Likely cause of death should be established by
a veterinarian and reported.
21) The report should include data from all animals or experimental units involved in the trials.
Cases which cannot be assessed due to a lack or loss of data should be reported, and their
distribution within the groups of animals indicated.
22) Concentration of the active substance(s) or agent(s) in the feedingstuffs to which the
additive is added should be periodically analysed and reported. A certiﬁcate of analysis of
the test item used in the study should be provided.
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23) Report the results for each endpoint measured/analysis carried out, with a measure of
precision (e.g. standard error or conﬁdence interval).
24) The report should include descriptive statistics plus detailed outcome of any statistical
analysis performed for all measured endpoints and each time point.
25) The measurement units should be speciﬁed for any result reported.
Discussion:
26) Interpretation of the results, taking into account the study objectives and hypotheses and
other relevant studies in the literature.
27) Comments on the study limitations including any potential sources of bias, any limitations of
the animal model and the imprecision associated with the results.
Conclusions:
28) The conclusions from the study should be drawn considering the objectives of the study,
the hypothesis and the outcome of the study.
Raw data, certiﬁcates of analysis:
29) The raw data should be provided in the form of an electronic database and should be
accompanied by a data dictionary containing the description of the variables and the
metadata needed to properly analyse them.
30) All codes, log and complete outputs for the ﬁnal statistical analysis (i.e. the results and
analysis reported) should be provided in electronic format.
31) The report should include the certiﬁcates of analysis for the different analysis performed,
reports of the veterinary observations (including, when performed, gross pathology and
histopathology, haematology, clinical chemistry, etc.).
Reports of in vitro studies should respect the principles described above, as appropriate.
7. Literature studies
Reference can be made to published studies to support the efﬁcacy of the additive (including the
demonstration of compatibility with other additives or components of the diet). The additive (active
substance(s)/agent(s)) in literature studies should be identical to that under application or, if not,
should still allow conclusions on the additive under application to be made. The concentration of the
additive (active substance(s)/agent(s)) in feed should reﬂect the conditions of use speciﬁed in the
application. The target species covered in the literature studies should be relevant to the application.
Application level, replicates, duration and endpoints measured should be in line with the requirements
listed in this guidance and should allow a conclusion on the efﬁcacy of the additive.
The list of relevant references included should be compiled in a reference management software
and provided in .RIS format. Copies of the relevant papers should be provided. The applicant must
ensure that terms and conditions asserted by any copyright holder of publications or information
submitted to EFSA are fully satisﬁed. The applicant should consult with copyright-licensing authorities
(i.e. at national level) for guidance on purchasing copyright licenses to reproduce any publications
provided to EFSA. The applicant remains solely responsible and liable for obtaining all necessary
authorisations and rights to use, reproduce and share the publications provided to EFSA.
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Abbreviations
FEEDAP The Panel on Additives and Products or Substances used in Animal Feed
AST anticoccidial sensitivity tests
UUC uninfected untreated control
IUC infected untreated control
IT infected treated
GLMM generalised linear mixed models
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Appendix A – Trial Protocol data sheet
FOR TERRESTRIAL ANIMALS
Identiﬁcation of the additive: Batch number:
Trial ID: Location:
Start date and exact duration of the study:
Number of treatment groups (+ control(s)): Replicates per group:
Total number of animals: Animals per replicate:








Sex: Age at start: Body weight at start:
Physiological stage: General health:
Diets (type(s)):
Presentation of the diet: Mash Pellet Extruded Other
Composition (main feedingstuffs):
Nutrient content (relevant nutrients and energy content)
Intended values:
Analysed values:
Date and nature of the examinations performed:
Method(s) of statistical evaluation used:
Therapeutic/preventive treatments (reason, timing, kind, duration):
Timing and prevalence of any undesirable consequences of treatment:
Date Signature Study Director
†: In case the concentration of the additive in complete feed/water may reﬂect insufﬁcient accuracy, the dose of the additive can
be given per animal/day or mg/kg body weight or as concentration in complementary feed.
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FOR AQUATIC ANIMALS
Identiﬁcation of the additive: Batch number:
Trial ID: Location:
Start date and exact duration of the study:
Number of treatment groups (+ control(s)): Replicates per group:
Total number of animals: Animals per replicate:








Colloquial name: Latin binomial:
Breed: Identiﬁcation procedure:
Sex*: Age at start: Body weight at start:
Physiological stage: General health:
Fork length at start: Lighting conditions:
Water quality including temperature, salinity, O2 and CO2:
Diets (type(s)):
Presentation of the diet: Mash Pellet Extruded Live feed Other
Composition (main feedingstuffs):
Nutrient content (relevant nutrients and energy content of the feed)
Intended values:
Analysed values:
Date and nature of the examinations performed:
Response measures for efﬁcacy and tolerance:
Method(s) of statistical evaluation used:
Therapeutic/preventive treatments (reason, timing, kind, duration):
Timing and prevalence of any undesirable consequences of treatment:
Date Signature Study Director
†: In case the concentration of the additive in complete feed/water may reﬂect insufﬁcient accuracy, the dose of the additive can
be given per animal/day or mg/kg body weight or as concentration in complementary feed.
*: Where possible.
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